Head to Head Comparison: Mobile-health Network Solutions (NASDAQ:MNDR) & MDxHealth (NASDAQ:MDXH)

Mobile-health Network Solutions (NASDAQ:MNDR) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Profitability

This table compares Mobile-health Network Solutions and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mobile-health Network Solutions	N/A	N/A	N/A
MDxHealth	-30.50%	-1,078.01%	-20.05%

Valuation and Earnings

This table compares Mobile-health Network Solutions and MDxHealth”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mobile-health Network Solutions	$7.65 million	0.13	-$3.38 million	N/A	N/A
MDxHealth	$90.05 million	2.02	-$38.07 million	($0.64)	-6.00

Mobile-health Network Solutions has higher earnings, but lower revenue than MDxHealth.

Risk & Volatility

Mobile-health Network Solutions has a beta of -2.11, indicating that its stock price is 311% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Mobile-health Network Solutions and MDxHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mobile-health Network Solutions	1	0	0	0	1.00
MDxHealth	1	0	4	0	2.60

MDxHealth has a consensus price target of $7.75, suggesting a potential upside of 101.82%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts clearly believe MDxHealth is more favorable than Mobile-health Network Solutions.

Summary

MDxHealth beats Mobile-health Network Solutions on 6 of the 10 factors compared between the two stocks.

About Mobile-health Network Solutions

Mobile-health Network Solutions, an investment holding company, provides telehealth solutions in Singapore. The company operates in two segments, Telemedicine and Other Services, and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The company also provides a range of primary healthcare services, including general medical consultations, treatment and management of acute and chronic conditions in adults and children, vaccinations, and health screenings for work permit applications, as well as pre-employment health screening, children's health services, geriatric care services, and minor surgical procedures. In addition, it offers healthcare and wellness-related products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace and forum, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical and health services. The company was founded in 2009 and is headquartered in Singapore.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.